Advertisement
Research Topics
Subscribe to Research Topics

The Lead

Embryonic Stem Cells in Trial for Diabetes

October 20, 2014 4:08 pm | by Cynthia Fox, Science Editor | Articles | Comments

As San Diego’s ViaCyte was in the midst of launching the first FDA-approved embryonic stem (ES) cell clinical trial for diabetes last week, Boston’s Harvard University reported that beta cells from ES cells “cured” diabetic mouse-models. Read more...

BioPontis Alliance, HNF Partner to Develop Treatments for CMT

October 20, 2014 2:29 pm | News | Comments

BioPontis Alliance for Rare Disease and the...

Lab-Developed Intestinal Organoids Form Mature Human Tissue in Mice

October 20, 2014 2:19 pm | News | Comments

Researchers have successfully transplanted “...

Revalesio’s Drug Has Potential to Treat Alzheimer’s Disease

October 20, 2014 12:07 pm | News | Comments

Revalesio Corporation and Rush University Medical...

View Sample

FREE Email Newsletter

Daily news and top headlines for drug research professionals

Taiho Receives FDA Fast Track Designation for Colorectal Cancer Drug

October 20, 2014 11:55 am | News | Comments

Taiho Oncology announced that the FDA granted Fast Track designation for TAS-102, an oral combination anticancer drug under investigation for the treatment of refractory metastatic colorectal cancer (mCRC), and that the company has initiated a rolling NDA submission to the FDA. Read more...

Anti-Abuse Label Approved for Painkiller Embeda

October 20, 2014 11:45 am | News | Comments

The U.S. Food and Drug Administration (FDA) says it has approved new labeling for another opioid designed to limit painkiller abuse. Read more...                                 

Metabolic Genetics Research Paves Way to Treating Diabetes, Obesity

October 20, 2014 11:39 am | News | Comments

Breaking down complex conditions such as Type 2 Diabetes and obesity into the specific metabolic proteins and processes that underlie them offers a new approach to studying the genetics of these diseases and how they are interrelated. Read more...

Advertisement

Clanotech Receives Orphan Drug Designation in the EU

October 20, 2014 10:48 am | News | Comments

Clanotech AB announced that its anti-fibrotic and anti-angiogenic candidate drug CLT-28643 received orphan drug designation by the European Medicines Agency (EMA) for prevention of scarring post glaucoma filtration surgery.  Read more...

NewLink Genetics, Genentech Enter Into Exclusive Worldwide License

October 20, 2014 10:44 am | News | Comments

NewLink Genetics Corp., a biopharmaceutical company focused on discovering, developing, and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced that they have entered into an exclusive worldwide license agreement with Genentech, a member of the Roche Group, for the development of NLG919, NewLink's IDO pathway inhibitor. Read more...

Sanofi, Regeneron Announce Phase 3 Study of Atopic Dermatitis Drug

October 20, 2014 10:32 am | News | Comments

Sanofi and Regeneron Pharmaceuticals, Inc. announced that the first patients have been dosed in a Phase 3 clinical study of dupilumab, an investigational therapy that blocks IL-4 and IL-13 signaling, in adults with moderate-to-severe atopic dermatitis (AD) that is not adequately controlled with topical AD medications. Read more..

Takeda, Orexigen Announce Availability of Weight-Management Drug

October 20, 2014 10:25 am | News | Comments

Takeda and Orexigen jointly announced that Contrave (naltrexone HCI and bupropion HCI) extended-release tablets are now available to patients by prescription in pharmacies across the United States. Read more...                 

Drug Restores Pleasure-Seeking Ahead of Other Antidepressant Effects

October 20, 2014 10:14 am | News | Comments

A drug being studied as a fast-acting mood-lifter restored pleasure-seeking behavior independent of — and ahead of — its other antidepressant effects, in an NIH trial. Within 40 minutes after a single infusion of ketamine, treatment-resistant depressed bipolar disorder patients experienced a reversal of a key symptom — loss of interest in pleasurable activities — which lasted up to 14 days. Read more...

Advertisement

EU Seeking to Create $1.27B Ebola Fund

October 20, 2014 9:47 am | by Raf Casert | News | Comments

European Union nations are working to reach 1 billion euros ($1.27 billion) in aid by the end of the week to fight Ebola in West Africa and are seeking a common approach to the crisis. Read more...

U.S. Monitors Health Care Worker Aboard Cruise Ship

October 17, 2014 1:43 pm | by Jim Kuhnhenn | News | Comments

A cruise ship with a Dallas health care worker aboard who is being monitored for signs of Ebola did not receive clearance to dock in Cozumel, Mexico, a day after Belize refused to let the passenger leave the vessel. Read more...

Chimerix Gets FDA OK to Test Drug for Ebola

October 17, 2014 1:34 pm | News | Comments

A North Carolina drugmaker plans to test its experimental antiviral drug in patients who have Ebola, after getting authorization from regulators at the Food and Drug Administration. Read more...

AbbVie Announces Results for HS Treatment

October 17, 2014 1:21 pm | News | Comments

AbbVie announced new results from PIONEER 2, a pivotal Phase 3 study, demonstrating the effect of Humira (adalimumab) in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa (HS), specifically the number of abscesses and inflammatory nodules. Read more...

UCSF, CDRD Sign Drug Development Agreement

October 17, 2014 1:06 pm | News | Comments

UCSFo and CDRD, a non-profit drug development center headquartered in Vancouver, Canada, announced a collaborative affiliation to identify potential medications and develop them to the stage where they are commercially attractive to private sector partners. Read more...

Advertisement

Amgen Files Lawsuit Against Sanofi, Regeneron for Patent Infringement

October 17, 2014 12:57 pm | News | Comments

Amgen announced that it filed a lawsuit against Sanofi and Regeneron Pharmaceuticals, Inc. for patent infringement of U.S. Patent Numbers 8,563,698, 8,829,165, and 8,859,741. Read more...

UN: We botched response to the Ebola outbreak

October 17, 2014 11:15 am | by Maria Cheng - AP Medical Writer - Associated Press | News | Comments

The World Health Organization has admitted that it botched attempts to stop the now-spiraling Ebola outbreak in West Africa, blaming factors including incompetent staff and a lack of information. Read more...

Anoro's COPD Drug Shows Improved Lung Function

October 17, 2014 11:07 am | News | Comments

Respiratory Medicine has published positive results from a third lung function study comparing the efficacy and safety of Anoro Ellipta. Read more...                                     

Pharmacyclics' Non-Chemo Treatment Approved in Europe

October 17, 2014 10:54 am | News | Comments

Pharmacyclics Inc. announced that the European Commission (EC) has granted marketing approval for Imbruvica (ibrutinib) throughout the 28 member states of the European Union (EU). Imbruvica, a first-in-class, oral, once-daily, non-chemotherapy treatment, now is approved to be marketed in Europe. Read more...

A Look At Latest Ebola Developments

October 17, 2014 10:40 am | News | Comments

The nation's top health officials tried to assure Congress that they can halt the spread of the Ebola virus in the U.S. despite mistakes that allowed two nurses to get the infection from a patient. Read more...

Scientific Breakthrough May Help Design Future Antibiotics

October 17, 2014 10:33 am | News | Comments

Scientists have used computer simulations to show how bacteria are able to destroy antibiotics – a breakthrough which may help develop drugs which can effectively tackle infections in the future. Read more...

FDA Votes to Keep Boxed Warning on Chantix

October 17, 2014 10:26 am | News | Comments

Federal health advisers say a bold-letter warning about suicide risks with Pfizer's Chantix should remain on the anti-smoking drug until it can reevaluated based on new, rigorous study information. Read more...

New Front in War on Alzheimer’s, Other Protein-Folding Diseases

October 17, 2014 10:12 am | News | Comments

A surprise discovery that overturns decades of thinking about how the body fixes proteins that come unraveled greatly expands opportunities for therapies to prevent diseases such as Alzheimer’s and Parkinson’s, which have been linked to the accumulation of improperly folded proteins in the brain. Read more...

A Novel Approach to Alzheimer’s Disease

October 17, 2014 9:57 am | by Daniel L. Alkon, M.D.,Chief Scientific Officer, Neurotrope Inc. and Toyota Chair in Neurodegenerative Disease, Scientific Director and Professor, Blanchette Rockefeller Neurosciences Institute | Articles | Comments

Alzheimer's disease (AD) afflicts more than 5 million people in the U.S. and 40 million worldwide, generating annual healthcare costs that exceed $200 billion in the U.S. and $600 billion globally. By 2050, AD is expected to strike more than 115 million patients per year, according to the Alzheimer’s Association. Read more...

Big Step in Battling Bladder Cancer

October 16, 2014 3:06 pm | News | Comments

The millions of people worldwide who suffer from the painful bladder disease known as interstitial cystitis (IC) may soon have a better, long-term treatment option, thanks to a controlled-release, implantable device invented by MIT researchers. Read more...

Big Step in Battling Bladder Disease

October 16, 2014 1:33 pm | News | Comments

Novel device that stays in the bladder and slowly releases drugs sells to pharmaceutical giant. Read more...                                                             

MIT, MGH Partner to Address Clinical Medicine Challenges

October 16, 2014 1:08 pm | News | Comments

A novel partnership between MIT and Massachusetts General Hospital (MGH) is addressing three major challenges in clinical medicine. Read more...                                          

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading